{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:48:03Z","timestamp":1793119683838,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Visceral Leishmaniasis is a systemic vector-borne infection with a poor prognosis if not treated. Classical antiparasitic therapy with liposomal amphotericin B (LAmB) is effective, but occasionally not well-tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentation:<\/jats:title>\n                    <jats:p>\n                      An 11-month-old male infant was admitted to our hospital due to prolonged fever, following an RSV infection. The patient had pale skin and splenomegaly, but was hemodynamically stable. An infectious cause was investigated through serology for\n                      <jats:italic toggle=\"yes\">Leishmania species<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Brucella melitensis<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">Toxoplasma gondii<\/jats:italic>\n                      , EBV, CMV, PB19 and\n                      <jats:italic toggle=\"yes\">Salmonella species<\/jats:italic>\n                      . After admission, the infant developed Hemophagocytic lymphohistiocytosis (HLH, with pancytopenia, triglycerides: 346 U\/L, ferritin: 1071\u2009ng\/mL; \u03b3-globulin was administered without clinical response). On the second hospitalization day, the Leishmania rapid test was positive, while blood polymerase chain reaction identified\n                      <jats:italic toggle=\"yes\">Leishmania Infantum<\/jats:italic>\n                      as the cause of infection, and LAmB was initiated. After the 4th dose, the patient developed hypokalemia, bradycardia and premature supraventricular complexes. The arrhythmia persisted despite electrolyte replacement; amphotericin-induced cardiotoxicity was suspected, and LAmB was discontinued. Oral miltefosine was started after approval by the National Public Health Organization, since the medicine was given in Greece for the first time to a pediatric patient. Miltefosine therapy lasted 1 month, with remission. Hepatotoxicity occurred at the end of the treatment and gradually resolved over the following 4 months with complete normalization of hepatic markers. The child remained asymptomatic at the 1-year follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Leishmaniasis should always be investigated in pediatric patients with secondary HLH, especially in endemic countries. Cardiotoxicity of LAmB is extremely rare; in this case, however, miltefosine is an effective and safe alternative.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005015","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T13:03:38Z","timestamp":1760706218000},"page":"e43-e46","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Liposomal Amphotericin B-induced Cardiac Arrhythmias in Infantile Visceral Leishmaniasis: A Case Report"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1412-9441","authenticated-orcid":false,"given":"Garyfallia","family":"Syridou","sequence":"first","affiliation":[{"name":"From the Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Karagiannidou","sequence":"additional","affiliation":[{"name":"From the Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7694-5686","authenticated-orcid":false,"given":"Maria Eleni","family":"Papakonstantinou","sequence":"additional","affiliation":[{"name":"From the Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Manzana Peteinelli","sequence":"additional","affiliation":[{"name":"From the Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Giannakopoulos","sequence":"additional","affiliation":[{"name":"From the Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Papaevangelou","sequence":"additional","affiliation":[{"name":"From the Third Department of Pediatrics, National and Kapodistrian University of Athens, University General Hospital ATTIKON, Athens, Greece."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis.","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40475-021-00232-7","article-title":"A review of leishmaniasis: current knowledge and future directions.","volume":"8","author":"Mann","year":"2021","journal-title":"Curr Trop Med Rep"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"345","DOI":"10.26502\/acmcr.96550627","article-title":"Visceral leishmaniasis in a 10-month-old Austrian girl epidemiological aspects and treatment strategies with review of the iiterature.","volume":"07","author":"Dornbusch","year":"2023","journal-title":"Arch Clin Med Case Rep"},{"key":"R7-20260109","first-page":"722","article-title":"Miltefosine in the treatment of leishmaniasis: clinical efficacy, safety and potential for resistance.","volume":"23","author":"Sundar","year":"2018","journal-title":"Trop Med Int Health"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1097\/MPH.0000000000001791","article-title":"Hemophagocytic lymphohistiocytosis in children: clinical profile and outcome.","volume":"42","author":"Simon","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00292-12","article-title":"Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.","volume":"56","author":"Dorlo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis.","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal amphotericin B (AmBisome): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions.","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"issue":"Suppl 4","key":"R12-20260109","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1093\/cid\/ciz076","article-title":"Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B.","volume":"68","author":"Groll","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/IPC.0000000000000647","article-title":"Liposomal amphotericin B\u2013associated cardiac arrest.","volume":"26","author":"Autry","year":"2018","journal-title":"Infect Dis Clin Pract"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes.","volume":"140","author":"Akin","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/08982109309150728","article-title":"Mechanism of action of amphotericin B at the cellular level. Its modulation by delivery system.","volume":"3","author":"Bolard","year":"1993","journal-title":"J Liposome Res"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13223-021-00582-x","article-title":"Asystolic cardiac arrest following liposomal amphotericin B infusion: anaphylaxis or complement activation-related pseudoallergy?","volume":"17","author":"Drewett","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"bcr2013202688","DOI":"10.1136\/bcr-2013-202688","article-title":"Atrioventricular block related to liposomal amphotericin B.","volume":"2014","author":"Sanches","year":"2014","journal-title":"BMJ Case Rep"},{"key":"R18-20260109","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mmcr.2016.10.001","article-title":"Reversible cardiomyopathy secondary to amphotericin B.","volume":"13","author":"Bandeira","year":"2016","journal-title":"Med Mycol Case Rep"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000457521","article-title":"Fatal overdose of amphotericin B in two preterm infants.","volume":"17","author":"Perlman","year":"1991","journal-title":"Dev Pharmacol Ther"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1097\/INF.0000000000001602","article-title":"M. Short-course regimens of liposomal amphotericin B for the treatment of Mediterranean visceral leishmaniasis in children: an 11-year retrospective study at a tertiary care center.","volume":"36","author":"Krepis","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20260109","first-page":"85","article-title":"Leishmaniasis and heart. Leishmaniasis y coraz\u00f3n.","volume":"92","author":"Farina","year":"2022","journal-title":"Arch Cardiol Mex"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tvjl.2016.11.015","article-title":"Comparison of myocardial damage among dogs at different stages of clinical leishmaniasis and dogs with idiopathic chronic kidney disease.","volume":"221","author":"Mart\u00ednez-Hern\u00e1ndez","year":"2017","journal-title":"Vet J"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Trop"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children.","volume":"205","author":"Rubiano","year":"2012","journal-title":"J Infect Dis"},{"key":"R26-20260109","first-page":"adv00322","article-title":"Cutaneous leishmaniasis treated with miltefosine: a case series of 10 paediatric patients.","volume":"100","author":"Ollech","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/ciy747","article-title":"Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral leishmaniasis in Eastern African children: an open-label, phase II clinical trial.","volume":"68","author":"Mbui","year":"2019","journal-title":"Clin Infect Dis"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:43:20Z","timestamp":1786049000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005015","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]}}}